KalVista stockholders elect three Class III directors at 2021 annual meeting

KalVista Pharmaceuticals, Inc.

Elected Albert Cha, Martin Edwards, and Nancy Stuart as Class III directors for three-year terms expiring 2024.
Ratified Deloitte & Touche as independent auditor for fiscal year ending April 30, 2022: 22.6M for, 13.6K against.
Approved non-binding advisory vote on named executive officer compensation: 19.7M for, 2.5M against.
All proposals passed; broker non-votes were 464,900 on director elections and compensation vote.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.